Zhuo Ying, Wu Yilong, Guo Ailin, Chen Siyuan, Su Jian
Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
Zhongguo Fei Ai Za Zhi. 2010 Jun;13(6):568-74. doi: 10.3779/j.issn.1009-3419.2010.06.020.
With the ongoing need to improve therapy for lung cancer, there has been an increasing interest in the development of reliable preclinical models to test novel therapeutics. The aim of this study is to establish a patient-derived lung cancer xenograft model in mice and to observe the biological characteristics of xenografts.
Surgically resected tumor specimens from patients with lung cancer were implanted in the subcutaneous layer of the NOD/ SCID mice. Cancer specimens of percutaneous lung biopsy by CT fluoroscopy were implanted into the subrenal capsule of nude mouse. The subcutaneous carcinoma was surgically removed when it grew to approximately 1.0 cm in diameter, and then re-transplanted into new nude mice. The growth process of transplanted tumor was observed. Expression of CEA, cytokeratin, and Ki67 were detected by immunohistochemistry. Mutations in the exons 18-21 of EGFR and exons 12,59 of K-ras of primary and xenograft tumors were examined. The cell cycle of xenograft tumor cells was analyzed by flow cytometry.
Eleven cases were conducted for NOD/SCID mice and nude mice modelling. The patient-derived lung cancer xenografts have been established successfully, and the tumor could be passed to new nude mice, including No 2 model (adenocasinoma), No. 3 model (small cell lung cancer), and No.5 model (squamous cell cancer). High homogeneity was found between xenograft tumors and human lung cancer in histopathology, immunohistochemical phenotype, and EGFR, K-ras mutation status. The S-phase fraction of xenograft cell cycle was prolonged, which indicated that the xenografts remains highly proliferated.
The xenotransplantation models established for patient-derived lung cancer in immune deficient mice. The success rate is 27%. This model system displayed the biological characteristics of human lung cancer, suggesting that it may provide a stable, reliable, and useful animal model in human lung cancer research.
随着改善肺癌治疗方法的需求不断增加,人们对开发可靠的临床前模型以测试新型疗法的兴趣日益浓厚。本研究的目的是在小鼠中建立患者来源的肺癌异种移植模型,并观察异种移植瘤的生物学特性。
将手术切除的肺癌患者肿瘤标本植入NOD/SCID小鼠的皮下层。通过CT透视经皮肺活检获取的癌标本植入裸鼠的肾包膜下。当皮下癌直径长至约1.0 cm时手术切除,然后重新移植到新的裸鼠体内。观察移植瘤的生长过程。通过免疫组织化学检测CEA、细胞角蛋白和Ki67的表达。检测原发性和异种移植瘤中EGFR外显子18 - 21和K-ras外显子12、59的突变。通过流式细胞术分析异种移植瘤细胞的细胞周期。
对11例进行了NOD/SCID小鼠和裸鼠建模。成功建立了患者来源的肺癌异种移植模型,肿瘤可传递给新的裸鼠,包括2号模型(腺癌)、3号模型(小细胞肺癌)和5号模型(鳞状细胞癌)。异种移植瘤与人类肺癌在组织病理学、免疫组化表型以及EGFR、K-ras突变状态方面具有高度一致性。异种移植细胞周期的S期比例延长,表明异种移植瘤仍具有高度增殖性。
在免疫缺陷小鼠中建立了患者来源的肺癌异种移植模型。成功率为27%。该模型系统展示了人类肺癌的生物学特性,表明它可能为人类肺癌研究提供一个稳定、可靠且有用的动物模型。